Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Plots Biosimilars Listing By 2023

Indian Firm Eyeing $1bn In Sales From Biosimilars In Two Years

Executive Summary

Biocon has high ambitions for its biosimilars arm, Biocon Biologics, with planned revenues of $1bn by the end its financial year ending in March 2022. The Indian firm, which has collaborated with Mylan for multiple biosimilar launches in developed markets, is aiming to list the business within three years.

You may also be interested in...



Biocon Biologics Bolstered By Goldman Sachs Investment

Goldman Sachs is investing around $150m in Biocon Biologics, valuing the Biocon subsidiary at just under $4bn.

Biocon Biologics Receives Further Investment As Value Hits $3.5bn

Biocon has received another influx of cash for its Biocon Biologics biosimilars arm, with a $30m investment from private equity group Tata Capital. Ahead of plans to realize $1bn of sales by its financial year ending March 2022, Biocon has been reorganizing and financing Biocon Biologics, with an initial public offering also on the cards by 2023.

Mylan And Biocon’s Semglee Insulin Glargine Approved In US

Mylan and Biocon have received FDA approval for their Semglee insulin glargine product, with a path to market seemingly clear after Mylan emerged victorious in several recent patent-litigation challenges. Meanwhile, the firm continues to strive towards an interchangeability designation that would make it a much more valuable opportunity.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel